Cargando…

A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques

The ongoing COVID-19 vaccine rollout is critical for reducing SARS-CoV-2 infections, hospitalizations, and deaths worldwide. Unfortunately, massive disparities exist in getting vaccines to vulnerable populations, including people living with HIV. Preliminary studies indicate that COVID-19 mRNA vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Megan A., Erasmus, Jesse H., Randall, Samantha, Archer, Jacob, Lewis, Thomas B., Brown, Brieann, Fredericks, Megan, Groenier, Skyler, Iwayama, Naoto, Ahrens, Chul, Garrison, William, Wangari, Solomon, Guerriero, Kathryn A., Fuller, Deborah H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724308/
https://www.ncbi.nlm.nih.gov/pubmed/34992610
http://dx.doi.org/10.3389/fimmu.2021.800723
_version_ 1784625894847938560
author O’Connor, Megan A.
Erasmus, Jesse H.
Randall, Samantha
Archer, Jacob
Lewis, Thomas B.
Brown, Brieann
Fredericks, Megan
Groenier, Skyler
Iwayama, Naoto
Ahrens, Chul
Garrison, William
Wangari, Solomon
Guerriero, Kathryn A.
Fuller, Deborah H.
author_facet O’Connor, Megan A.
Erasmus, Jesse H.
Randall, Samantha
Archer, Jacob
Lewis, Thomas B.
Brown, Brieann
Fredericks, Megan
Groenier, Skyler
Iwayama, Naoto
Ahrens, Chul
Garrison, William
Wangari, Solomon
Guerriero, Kathryn A.
Fuller, Deborah H.
author_sort O’Connor, Megan A.
collection PubMed
description The ongoing COVID-19 vaccine rollout is critical for reducing SARS-CoV-2 infections, hospitalizations, and deaths worldwide. Unfortunately, massive disparities exist in getting vaccines to vulnerable populations, including people living with HIV. Preliminary studies indicate that COVID-19 mRNA vaccines are safe and immunogenic in people living with HIV that are virally suppressed with potent antiretroviral therapy but may be less efficacious in immunocompromised individuals. This raises the concern that COVID-19 vaccines may be less effective in resource poor settings with limited access to antiretroviral therapy. Here, we evaluated the immunogenicity of a single dose COVID-19 replicon RNA vaccine expressing Spike protein (A.1) from SARS-CoV-2 (repRNA-CoV2S) in immunocompromised, SIV infected and immune competent, naïve pigtail macaques. Moderate vaccine-specific cellular Th1 T-cell responses and binding and neutralizing antibodies were induced by repRNA-CoV2S in SIV infected animals and naïve animals. Furthermore, vaccine immunogenicity was elicited even among the animals with the highest SIV viral burden or lowest peripheral CD4 counts prior to immunization. This study provides evidence that a SARS-CoV-2 repRNA vaccine could be employed to induce strong immunity against COVID-19 in HIV infected and other immunocompromised individuals.
format Online
Article
Text
id pubmed-8724308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87243082022-01-05 A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques O’Connor, Megan A. Erasmus, Jesse H. Randall, Samantha Archer, Jacob Lewis, Thomas B. Brown, Brieann Fredericks, Megan Groenier, Skyler Iwayama, Naoto Ahrens, Chul Garrison, William Wangari, Solomon Guerriero, Kathryn A. Fuller, Deborah H. Front Immunol Immunology The ongoing COVID-19 vaccine rollout is critical for reducing SARS-CoV-2 infections, hospitalizations, and deaths worldwide. Unfortunately, massive disparities exist in getting vaccines to vulnerable populations, including people living with HIV. Preliminary studies indicate that COVID-19 mRNA vaccines are safe and immunogenic in people living with HIV that are virally suppressed with potent antiretroviral therapy but may be less efficacious in immunocompromised individuals. This raises the concern that COVID-19 vaccines may be less effective in resource poor settings with limited access to antiretroviral therapy. Here, we evaluated the immunogenicity of a single dose COVID-19 replicon RNA vaccine expressing Spike protein (A.1) from SARS-CoV-2 (repRNA-CoV2S) in immunocompromised, SIV infected and immune competent, naïve pigtail macaques. Moderate vaccine-specific cellular Th1 T-cell responses and binding and neutralizing antibodies were induced by repRNA-CoV2S in SIV infected animals and naïve animals. Furthermore, vaccine immunogenicity was elicited even among the animals with the highest SIV viral burden or lowest peripheral CD4 counts prior to immunization. This study provides evidence that a SARS-CoV-2 repRNA vaccine could be employed to induce strong immunity against COVID-19 in HIV infected and other immunocompromised individuals. Frontiers Media S.A. 2021-12-21 /pmc/articles/PMC8724308/ /pubmed/34992610 http://dx.doi.org/10.3389/fimmu.2021.800723 Text en Copyright © 2021 O’Connor, Erasmus, Randall, Archer, Lewis, Brown, Fredericks, Groenier, Iwayama, Ahrens, Garrison, Wangari, Guerriero and Fuller https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
O’Connor, Megan A.
Erasmus, Jesse H.
Randall, Samantha
Archer, Jacob
Lewis, Thomas B.
Brown, Brieann
Fredericks, Megan
Groenier, Skyler
Iwayama, Naoto
Ahrens, Chul
Garrison, William
Wangari, Solomon
Guerriero, Kathryn A.
Fuller, Deborah H.
A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title_full A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title_fullStr A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title_full_unstemmed A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title_short A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques
title_sort single dose sars-cov-2 replicon rna vaccine induces cellular and humoral immune responses in simian immunodeficiency virus infected and uninfected pigtail macaques
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724308/
https://www.ncbi.nlm.nih.gov/pubmed/34992610
http://dx.doi.org/10.3389/fimmu.2021.800723
work_keys_str_mv AT oconnormegana asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT erasmusjesseh asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT randallsamantha asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT archerjacob asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT lewisthomasb asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT brownbrieann asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT fredericksmegan asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT groenierskyler asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT iwayamanaoto asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT ahrenschul asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT garrisonwilliam asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT wangarisolomon asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT guerrierokathryna asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT fullerdeborahh asingledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT oconnormegana singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT erasmusjesseh singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT randallsamantha singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT archerjacob singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT lewisthomasb singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT brownbrieann singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT fredericksmegan singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT groenierskyler singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT iwayamanaoto singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT ahrenschul singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT garrisonwilliam singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT wangarisolomon singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT guerrierokathryna singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques
AT fullerdeborahh singledosesarscov2repliconrnavaccineinducescellularandhumoralimmuneresponsesinsimianimmunodeficiencyvirusinfectedanduninfectedpigtailmacaques